The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2017

Filed:

Aug. 16, 2013
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

James M. Apgar, Highland, NJ (US);

Ashok Arasappan, Bridgewater, NJ (US);

Tesfaye Biftu, Freehold, NJ (US);

Ping Chen, Edison, NJ (US);

Danqing Feng, Green Brook, NJ (US);

Erin Guidry, Cranford, NJ (US);

Jacqueline Hicks, Scotch Plains, NJ (US);

Ahmet Kekec, Jersey City, NJ (US);

Kenneth J. Leavitt, Mount Laurel, NJ (US);

Bing Li, Towaco, NJ (US);

Iyassu Sebhat, Jersey City, NJ (US);

Xiaoxia Qian, New York, NY (US);

Lan Wei, Berkeley Heights, NJ (US);

Robert R. Wilkening, Maplewood, NJ (US);

Zhicai Wu, Montvale, NJ (US);

Assignee:

Merck Shapr & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 493/04 (2006.01); A61K 31/366 (2006.01); A61K 31/397 (2006.01); A61K 31/4985 (2006.01); A61K 31/4184 (2006.01); A61K 31/4196 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/454 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 493/04 (2013.01); A61K 31/366 (2013.01); A61K 31/397 (2013.01); A61K 31/4184 (2013.01); A61K 31/4196 (2013.01); A61K 31/427 (2013.01); A61K 31/4245 (2013.01); A61K 31/454 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01);
Abstract

The novel benzimidazole hexahydrofuro[3,2-B]furan derivatives of the present invention are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.


Find Patent Forward Citations

Loading…